COST Action 17103 - Delivery of Antisense RNA Therapeutics

Datos básicos

Código:

EU19/34

Dotación:

Año Inicial:

2019

Año final:

2023

Objetivos del proyecto

Antisense oligonucleotides (ASOs) are a new class of drugs that, through very specific targeting, could correct genetic defects for rare inherited diseases, modulate autoimmune or neurodegenerative diseases or target tumors or viruses. However, only a few of such drugs are currently in the market and they have been less effective as expected. Regarding delivery, the ASO field is fragmented, with researchers in academia and industry working in isolation on specific diseases, generally focusing on therapeutic effects in target tissues. The main aim of the Delivery of Antisense RNA ThERapeutics (DARTER) Action is to use networking and capacity building in the field of nucleic acid therapy delivery to allow RNA-targeting nucleic acid drugs to reach their full potential and become a mainstream therapeutic option.

Unidades de investigación

• NANOMEDICINA

  

  Investigador Responsable

  Mónica López Fanarraga

  monica.lopez@unican.es